Shaanxi Micot Pharmaceutical Technology Co., Ltd.

This study tests a new drug, MT200605, in 360 people who had a stroke within the last 24 hours. The drug aims to protect brain cells and reduce damage. Participants receive either a low, medium, or high dose of the drug or a placebo, along with standard care. The main goal is to …

This study tests a new medicine called MT1013 for people with secondary hyperparathyroidism who are on dialysis. The goal is to see if MT1013 works better than the current standard drug, cinacalcet, at lowering parathyroid hormone levels. About 424 adults will take either MT1013 …

This early-phase study looks at how a new experimental drug called MT1013 is absorbed, broken down, and removed from the body in 6 adults on hemodialysis who have secondary hyperparathyroidism. Participants receive a single dose containing a radioactive tracer so researchers can …